Vanflyta (quizartinib) — Medica
Myeloid or Lymphoid Neoplasms with eosinophilia and FLT3 rearrangement
Initial criteria
- For Acute Myeloid Leukemia: age ≥ 18 years AND FLT3-ITD mutation-positive disease as detected by an approved test
- For Myeloid or Lymphoid Neoplasms: age ≥ 18 years AND eosinophilia AND tumor has an FLT3 rearrangement
Approval duration
1 year